Researchers Studying Oral Medication to See if it Protects the Brain During Radiation Therapy Treatment for Primary Central Nervous System Tumors

Phase: Recruiting

First Posted: March

Condition(s): Central Nervous System (CNS) Tumors

NCT Number: NCT04939597 Other Study ID Number(s): ACCL2031

What Is the Purpose of This Study?

To see if oral medication memantine protects the brain during radiation therapy treatment for primary central nervous system tumors.

Who Can Take Part in This Study?

People who may be eligible for this study:

  • Primary central nervous system tumors that have not received prior cranial radiotherapy.
  • Are 4-17 years old.

For a full list of eligibility requirements, visit https://clinicaltrials.gov/study/NCT04939597

What Will Happen During This Study?

Patients randomized to receive oral medication memantine or placebo daily for 24 weeks. Patients also complete cognitive function testing and quality of life (QOL) surveys at baseline, end of radiation therapy, and at 3, 6, 12, 24, and 48 months. Patients may optionally undergo blood sample collection throughout the trial.

Principal Investigator

Mark A. Ranalli
MD

Hematology & Oncology

Discover More Research
Explore additional studies relating to neuro-oncology